Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Aug 27, 2025; 17(8): 104568
Published online Aug 27, 2025. doi: 10.4240/wjgs.v17.i8.104568
Published online Aug 27, 2025. doi: 10.4240/wjgs.v17.i8.104568
Clinical observation of combined transarterial chemoembolization and targeted therapy in postoperative recurrent colorectal cancer with liver metastasis
Jian-Yu Liu, Zhi-Hui Liang, Jing-Lei Liu, Liang Li, Bao Cui, Department of Interventional Treatment, Bethune International Peace Hospital of PLA, Shijiazhuang 050082, Hebei Province, China
Tie-Gang Li, Department of Oncology, Bethune International Peace Hospital of PLA, Shijiazhuang 050082, Hebei Province, China
Author contributions: Liu JY and Liang ZH were the guarantors and designed the study; Liu JY, Liang ZH, and Liu JL participated in the acquisition, analysis, and interpretation of the data and drafted the initial manuscript; Li L, Cui B, and Li TG revised the article critically for important intellectual content. All the authors participated in this study and jointly reviewed and edited the manuscript.
Supported by 2023 Hebei Provincial Medical Scientific Research Project Plan, No. 20231304.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Bethune International Peace Hospital of PLA, No. BIPH-LL-2022-003.
Informed consent statement: Written informed consent was obtained from all participants.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: There is no available data.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian-Yu Liu, MD, Associate Chief Physician, Department of Inter
Received: March 26, 2025
Revised: April 21, 2025
Accepted: June 30, 2025
Published online: August 27, 2025
Processing time: 152 Days and 4.8 Hours
Revised: April 21, 2025
Accepted: June 30, 2025
Published online: August 27, 2025
Processing time: 152 Days and 4.8 Hours
Core Tip
Core Tip: This study investigates the combination of transarterial chemoembolization and targeted therapies (bevacizumab, cetuximab, and panitumumab) for the treatment of postoperative recurrent colorectal cancer with liver metastasis. The results indicate that this multimodal approach improved overall survival (28 months) and progression-free survival (12 months), with bevacizumab showing superior outcomes. The treatment is well tolerated, with manageable adverse events, and significantly enhances the patients’ quality of life. This combination therapy has the potential to be an effective and safe strategy for this challenging clinical scenario.